Transient security company business

Pharmaceuticals Research and development lead to the main business and the Committee with regard to the transient analysis of the company's business.

Disclosure of data to a meaningful part of the business introduction excerpt via cleanup.

The initial model development and research in the business yet expensive corporate business appears in the form.

The development phase of the program	Drug-resistant tuberculosis cure Q203 (United States FDA clinical phase in progress) Atopic Dermatitis remedy Q301 (United States FDA clinical 2-phase in progress) Anti-cancer immune/resistant Cancer Therapeutics Q701 (non-clinical in progress)
Research program	5LO undermines asthma remedy, CDK7 inhibition of anticancer drugs

   

Successful development in the short term are likely to be a cure for atopic dermatitis Q301 programs and drug resistance tuberculosis cure Q203 program is our short-term growth in the company's stable financial structure by tow, blockbuster sales anticipated anti-cancer immune/resistant Cancer Therapeutics Q 701 is growth expected to do as

   

Product development status